[{"id":"333c53ae-6310-43e6-88cd-edfda84ac25b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01101581","created_at":"2021-01-18T04:21:31.821Z","updated_at":"2024-07-02T16:36:26.198Z","phase":"Phase 1/2","brief_title":"Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL","source_id_and_acronym":"NCT01101581","lead_sponsor":"Gilead Sciences","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LymphoCide Y-90 (epratuzumab Y-90) • Veltucyn (veltuzumab)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/01/2010","start_date":" 05/01/2010","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 03/01/2017","study_completion_date":" 03/01/2017","last_update_posted":"2021-08-18"},{"id":"b6df07b6-a88e-4791-862f-2c9826b94a75","acronym":"LIFT","url":"https://clinicaltrials.gov/study/NCT01275209","created_at":"2021-02-26T05:52:10.861Z","updated_at":"2024-07-02T16:36:37.648Z","phase":"Phase 1","brief_title":"Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma","source_id_and_acronym":"NCT01275209 - LIFT","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CD40","pipe":"","alterations":" ","tags":["CD40"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bendamustine • LymphoCide Y-90 (epratuzumab Y-90) • lucatumumab (CHIR 12.12)"],"overall_status":"Completed","enrollment":" Enrollment 1","initiation":"Initiation: 02/01/2011","start_date":" 02/01/2011","primary_txt":" Primary completion: 05/01/2012","primary_completion_date":" 05/01/2012","study_txt":" Completion: 05/01/2012","study_completion_date":" 05/01/2012","last_update_posted":"2020-12-08"},{"id":"015a4b5c-9024-44cd-bf9c-680f009004a6","acronym":"EPRALLO","url":"https://clinicaltrials.gov/study/NCT02577094","created_at":"2021-01-18T12:29:58.002Z","updated_at":"2024-07-02T16:37:26.429Z","phase":"Phase 1/2","brief_title":"Testing a Reduced Conditioning Regimen FB2A2 Preceded by a Fractionated Radio-immunotherapy (RIT) With 90Y-Epratuzumab Before Allogeneic Stem Cell Transplantation for Patients With Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT02577094 - EPRALLO","lead_sponsor":"Nantes University Hospital","biomarkers":" CD22","pipe":" | ","alterations":" CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fludarabine IV • busulfan • Epratucyn (epratuzumab) • LymphoCide Y-90 (epratuzumab Y-90)"],"overall_status":"Withdrawn","enrollment":"","initiation":"","start_date":"","primary_txt":" Primary completion: 01/01/2017","primary_completion_date":" 01/01/2017","study_txt":" Completion: 01/01/2017","study_completion_date":" 01/01/2017","last_update_posted":"2017-01-19"}]